Amgen is a drug manufacturers - general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $317.38 – . Amgen employs 28,000 staff and has a trailing 12-month revenue of around $36 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Amgen stock price (NASDAQ: AMGN)
Use our graph to track the performance of AMGN stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Amgen stock undervalued or overvalued?
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's P/E ratio
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Amgen shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Amgen's PEG ratio
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9577. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.5 billion.
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.
Amgen financials
Revenue TTM
$36 billion
Operating margin TTM
34.15%
Gross profit TTM
$25.2 billion
Return on assets TTM
7.71%
Return on equity TTM
81.71%
Profit margin
19.47%
Book value
$17.86
Market Capitalization
$177.6 billion
TTM: trailing 12 months
Amgen's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Amgen's total ESG risk score
Total ESG risk: 20.95
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Amgen's environmental score
Environmental score: 1.53/100
Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Amgen's social score
Social score: 15.13/100
Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Amgen's governance score
Governance score: 5.8/100
Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Amgen's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Amgen Inc was last rated for ESG on: 2019-01-01.
Total ESG score
20.95
Total ESG percentile
23.7
Environmental score
1.53
Environmental score percentile
3
Social score
15.13
Social score percentile
3
Governance score
5.8
Governance score percentile
3
Level of controversy
2
Amgen share dividends
Dividend payout ratio: 43.53% of net profits
Recently Amgen has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $9.39 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 11 December 2025. The latest dividend was paid out to all shareholders who bought their shares by 20 November 2025 (the "ex-dividend date").
Have Amgen's shares ever split?
Amgen's shares were
split on a 2:1 basis on 21 November 1999
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Amgen share price volatility
Over the last 12 months, Amgen's shares have ranged in value from as little as $245.3149 up to $346.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.447. This would suggest that Amgen's shares are less volatile than average (for this exchange).
Amgen overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co.
Frequently asked questions
null What percentage of Amgen is owned by insiders or institutions? Currently 0.212% of Amgen shares are held by insiders and 83.824% by institutions.How many people work for Amgen? Latest data suggests 28,000 work at Amgen.When does the fiscal year end for Amgen? Amgen's fiscal year ends in December.Where is Amgen based? Amgen's address is: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799What is Amgen's ISIN number? Amgen's international securities identification number is: US0311621009What is Amgen's CUSIP number? Amgen's Committee on Uniform Securities Identification Procedures number is: 031162100
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
